Skip to main content
MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. logo

MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 688062 ISIN · CNE100005RD2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 541 across all filing types
Latest filing 2023-12-29 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688062

About MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.

https://www.mabwell.com/en/

Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of therapeutic antibodies and innovative biologics. The company maintains an integrated R&D and manufacturing platform covering the full drug lifecycle, from target discovery and preclinical research to clinical development and commercial production. Its therapeutic pipeline addresses critical needs in oncology, autoimmune diseases, metabolic disorders, ophthalmology, and infectious diseases. Mabwell leverages proprietary technology platforms, including antibody-drug conjugates (ADCs), bispecific antibodies, and high-throughput screening, to develop a diverse portfolio of novel drug candidates and biosimilars. The organization is committed to delivering high-quality, accessible therapeutic solutions through its end-to-end biotechnological capabilities.

Recent filings

Filing Released Lang Actions
董事会议事规则（2023年12月）
Governance Information Classification · 95% confidence The document is titled "董事会议事规则" which translates to "Board Meeting Rules" or "Rules of Procedure for the Board of Directors." It details the composition, responsibilities, meeting procedures, committees, voting rules, and other governance-related aspects of the company's board of directors. There is no financial data, audit information, or report content. It is a governance document outlining internal rules and board structure. Therefore, it fits the category of Governance Information (CGR). The document length is substantial and it is not an announcement or a brief notice, so it is not a report publication announcement or regulatory filing. Hence, the classification is CGR with high confidence.
2023-12-29 Chinese
迈威生物独立董事关于第二届董事会第四次会议相关事项的事前认可和独立意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors regarding the pre-approval and independent opinions on matters to be discussed at the company's second board meeting. It includes opinions on daily related-party transactions and changes to fundraising account management. The content focuses on governance and compliance with regulatory requirements, rather than financial results or audit findings. The document is relatively short (1228 characters) and does not contain financial statements or detailed financial data. It is not an announcement of voting results but an independent opinion related to board meeting agenda items. This fits best under Board/Management Information (MANG), which covers announcements related to board or senior management matters, including independent director opinions on board meeting issues.
2023-12-29 Chinese
董事会薪酬与考核委员会工作细则（2023年12月）
Governance Information Classification · 100% confidence The document is titled as the "Board of Directors Remuneration and Assessment Committee Work Rules" for a company, detailing the structure, responsibilities, meeting procedures, and governance of the remuneration and assessment committee. It focuses on internal governance policies related to board and senior management compensation and assessment. There are no financial statements, earnings data, or regulatory filings of financial results. It is not an announcement of a report but a governance document outlining committee rules and procedures. This fits the definition of Governance Information (CGR), which covers internal rules, board structure, and governance practices.
2023-12-29 Chinese
迈威生物关于修订《公司章程》并办理工商变更登记及修订、制定公司部分治理制度的公告
Governance Information Classification · 95% confidence The document is an announcement from the board of directors of Maiwei (Shanghai) Biotechnology Co., Ltd. regarding the revision of the company's Articles of Association and certain governance rules. It details the changes made to the company's governance documents, including the Articles of Association, shareholder meeting rules, board meeting rules, and independent director work systems. The document also states that these changes require approval at the upcoming extraordinary shareholders' meeting. The content focuses on governance structure and internal rules rather than financial results or audit information. It is not a full annual or interim report, nor is it a call transcript or earnings release. It is not a proxy solicitation or voting results announcement but rather a formal disclosure of governance changes. Therefore, the document fits best under the category of Governance Information (CGR). The document length (6337 characters) and detailed content support this classification with high confidence.
2023-12-29 Chinese
监事会议事规则（2023年12月）
Governance Information Classification · 95% confidence The document is titled '迈威（上海）生物科技股份有限公司 监事会议事规则', which translates to 'Supervisory Board Meeting Rules' of Maiwei (Shanghai) Biotechnology Co., Ltd. The content details the rules and procedures for the supervisory board meetings, including their powers, meeting convocations, voting procedures, record keeping, and execution of resolutions. It references relevant laws and regulations such as the Company Law of China, Securities Law, and listing rules. This document is a governance-related internal rules document rather than a financial report, announcement, or other filing types. It does not contain financial data, audit opinions, or shareholder voting results. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2023-12-29 Chinese
独立董事工作制度（2023年12月）
Governance Information Classification · 95% confidence The document is titled '迈威（上海）生物科技股份有限公司 独立董事工作制度' which translates to 'Maiwei (Shanghai) Biotechnology Co., Ltd. Independent Director Work System'. The content details the rules, responsibilities, qualifications, and procedures related to independent directors of the company. It includes governance-related provisions such as appointment, duties, independence criteria, special powers, and communication mechanisms of independent directors. There is no financial data, earnings information, or report publication announcement. The document is a governance-related internal regulation or policy document. Therefore, it fits best under Governance Information (CGR).
2023-12-29 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.